secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-10-14T11:15:22+00:00
Accession:  0001437749-26-032600
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Eton licenses LIBERVANT buccal film from Aquestive for $10M upfront, up to $47.5M milestones
--------------------------------------------------------------------------------

- Eton paid Aquestive a $10.0M upfront license fee for exclusive U.S. rights to LIBERVANT (diazepam) buccal film for seizure clusters in epilepsy.
- Milestones: $10.0M on first U.S. commercial sale (cut to $5.0M without full ages 2-5 approval), $2.5M on FDA approval for ages 6-11, up to $35M tied to annual net sales.
- Eton pays mid-teens percentage royalties on U.S. net sales; Aquestive is exclusive manufacturer under a 20-year Supply Agreement.
- Commercial launch anticipated April 2027 subject to final FDA approval; tentative approval covers ages 2-5 and 12+, with full 12+ approval expected after VALTOCO exclusivity ends Jan 10, 2027.
- Cited U.S. seizure rescue market exceeds $450M annually; in a 101-patient survey, 71% preferred film vs 13% nasal spray; LIBERVANT holds Orphan Drug Designation (Nov 2016) and patents to 2038.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926032600/0001437749-26-032600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926032600/eton20261013_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer